Dechra Pharmaceuticals PLC
DCHPF · OTC
6/30/2023 | 12/31/2022 | 6/30/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $384 | $377 | $349 | $332 |
| % Growth | 1.8% | 8% | 5.1% | – |
| Cost of Goods Sold | $173 | $159 | $153 | $144 |
| Gross Profit | $211 | $219 | $196 | $189 |
| % Margin | 55% | 57.9% | 56.1% | 56.8% |
| R&D Expenses | $62 | $28 | $56 | $15 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $208 | $143 | $137 | $116 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $264 | $180 | $167 | $131 |
| Operating Income | -$30 | $47 | $38 | $57 |
| % Margin | -7.8% | 12.4% | 11% | 17.3% |
| Other Income/Exp. Net | -$36 | -$17 | -$14 | -$4 |
| Pre-Tax Income | -$66 | $30 | $24 | $53 |
| Tax Expense | -$15 | $7 | $7 | $13 |
| Net Income | -$51 | $23 | $18 | $41 |
| % Margin | -13.1% | 6% | 5% | 12.2% |
| EPS | -0.44 | 0.199 | 0.16 | 0.38 |
| % Growth | -321.6% | 23.8% | -57.8% | – |
| EPS Diluted | -0.44 | 0.199 | 0.16 | 0.38 |
| Weighted Avg Shares Out | 113 | 113 | 108 | 109 |
| Weighted Avg Shares Out Dil | 114 | 114 | 109 | 109 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $9 | $0 | $0 |
| Interest Expense | $13 | $9 | $5 | $4 |
| Depreciation & Amortization | $37 | $9 | $32 | $7 |
| EBITDA | -$16 | $47 | $61 | $65 |
| % Margin | -4.1% | 12.5% | 17.5% | 19.5% |